Memantina Grindeks

Memantine Hydrochloride, the active ingredient in Memantina Grindeks, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantina Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Grindeks is a NMDA receptor antagonist used in the management of Alzheimer’s disease. Alzheimer's disease (moderate to severe): provides symptomatic relief by improving cognition, behavior, and daily functioning.

Memantina Grindeks may cause a range of adverse reactions.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary mental disorientation. - Fatigue: increased tiredness. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Hepatic dysfunction: abnormal liver enzymes. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: new or worsening hallucinations or delusions.

When prescribing Memantina Grindeks, clinicians should consider several safety factors. - Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - History of seizures: use with caution and monitor closely. - Concomitant NMDA antagonists: avoid combined use to reduce additive toxicity. - Pregnancy: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Grindeks can interact with other medicines, necessitating careful review.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS effects and potential for severe dizziness. - Cimetidine or quinidine: may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive benefits. - CNS depressants (e.g., benzodiazepines): enhanced sedation. - SSRIs or SNRIs: possible increase in side‑effect profile. - Diuretics: monitor renal function and electrolytes.